Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study
Both immediate and deferred switching from a PI/r-based to a DTG-based regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved lipid profiles. Abstract Background Both immediate and deferred switc...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2019-02, Vol.68 (4), p.597-606 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 606 |
|---|---|
| container_issue | 4 |
| container_start_page | 597 |
| container_title | Clinical infectious diseases |
| container_volume | 68 |
| creator | Gatell, José M. Assoumou, Lambert Moyle, Graeme Waters, Laura Johnson, Margaret Domingo, Pere Fox, Julie Martinez, Esteban Stellbrink, Hans-Jürgen Guaraldi, Giovanni Masia, Mar Gompels, Mark De Wit, Stephane Florence, Eric Esser, Stefan Raffi, François Stephan, Christoph Rockstroh, Juergen Giacomelli, Andrea Vera, Jaime Bernardino, José Ignacio Winston, Alan Saumoy, Maria Gras, Julien Katlama, Christine Pozniak, Anton L. |
| description | Both immediate and deferred switching from a PI/r-based to a DTG-based regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved lipid profiles.
Abstract
Background
Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile.
Methods
European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with a Framingham score ≥10% were eligible if HIV RNA was |
| doi_str_mv | 10.1093/cid/ciy505 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03727804v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26621380</jstor_id><oup_id>10.1093/cid/ciy505</oup_id><sourcerecordid>26621380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-cb03b02b1aadffb51c8ef055d6cd3bfdf977a94610c761eb6584af930f77af3c3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhyMEoqVw4Q7ypRIgBcbxOn-Oy5ayK61E1UIRp8hxxlmXJA62s2hvXDnzDDwNb9EnwauUIi4cRjP6zaff5YuixxReUijYK6nrMDsO_E50SDnL4pQX9G64gefxLGf5QfTAuSsASnPg96ODpChowiA7jH6tug5rLTySS7RudOQEFVqLNbn4qr3c6L4hp9Z0RJDXxjgfHmfWeBQOyarf6Ep7Y6-__ahCUJNzbHSHPfEm8CemHT02Vmy1jf_9655camta02gp2nZHLsZhsOj2zJnwGnvvyEftN2Spmw1ZCFtrsxVOjq2w5Fy7z8RYMm-QXH__yYF8QmHdw-ieEq3DRzf7KPpw-ub9Yhmv371dLebrWM6g8LGsgFWQVFSIWqmKU5mjAs7rVNasUrUqskwUs5SCzFKKVcrzmVAFAxVyxSQ7ip5PvRvRloPVnbC70ghdLufrcp8By5Ish9mWBvbZxA7WfBnR-bLTTmLbih7N6MoEeJqlScGygL6YUGmNcxbVbTeFci-6DKLLSXSAn970jlUQeIv-MRuA4wkw4_D_oicTd-WCyL89aZpQlgP7DSEvwGI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2056762937</pqid></control><display><type>article</type><title>Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gatell, José M. ; Assoumou, Lambert ; Moyle, Graeme ; Waters, Laura ; Johnson, Margaret ; Domingo, Pere ; Fox, Julie ; Martinez, Esteban ; Stellbrink, Hans-Jürgen ; Guaraldi, Giovanni ; Masia, Mar ; Gompels, Mark ; De Wit, Stephane ; Florence, Eric ; Esser, Stefan ; Raffi, François ; Stephan, Christoph ; Rockstroh, Juergen ; Giacomelli, Andrea ; Vera, Jaime ; Bernardino, José Ignacio ; Winston, Alan ; Saumoy, Maria ; Gras, Julien ; Katlama, Christine ; Pozniak, Anton L.</creator><creatorcontrib>Gatell, José M. ; Assoumou, Lambert ; Moyle, Graeme ; Waters, Laura ; Johnson, Margaret ; Domingo, Pere ; Fox, Julie ; Martinez, Esteban ; Stellbrink, Hans-Jürgen ; Guaraldi, Giovanni ; Masia, Mar ; Gompels, Mark ; De Wit, Stephane ; Florence, Eric ; Esser, Stefan ; Raffi, François ; Stephan, Christoph ; Rockstroh, Juergen ; Giacomelli, Andrea ; Vera, Jaime ; Bernardino, José Ignacio ; Winston, Alan ; Saumoy, Maria ; Gras, Julien ; Katlama, Christine ; Pozniak, Anton L. ; European Network for AIDS Treatment 022 (NEAT022) Study Group</creatorcontrib><description>Both immediate and deferred switching from a PI/r-based to a DTG-based regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved lipid profiles.
Abstract
Background
Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile.
Methods
European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with a Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients were randomized to switch from PI/r to DTG immediately (DTG-I) or to deferred switch at week 48 (DTG-D). Week 96 endpoints were proportion of patients with HIV RNA <50 copies/mL, percentage change of lipid fractions, and adverse events (AEs).
Results
Four hundred fifteen patients were randomized: 205 to DTG-I and 210 DTG-D. The primary objective of noninferiority at week 48 was met. At week 96, treatment success rate was 92.2% in the DTG-I arm and 87% in the DTG-D arm (difference, 5.2% [95% confidence interval, -.6% to 11%]). There were 5 virological failures in the DTG-I arm and 5 (1 while on PI/r and 4 after switching to DTG) in the DTG-D arm without selection of resistance mutations. There was no significant difference in terms of grade 3 or 4 AEs or treatment-modifying AEs. Total cholesterol and other lipid fractions (except high-density lipoprotein) significantly (P < .001) improved both after immediate and deferred switching to DTG overall and regardless of baseline PI/r strata.
Conclusions
Both immediate and deferred switching from a PI/r to a DTG regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved the lipid profile.
Clinical Trials Registration
NCT02098837 and EudraCT: 2013-003704-39.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciy505</identifier><identifier>PMID: 29912307</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antiretroviral Therapy, Highly Active - methods ; ARTICLES AND COMMENTARIES ; Cardiovascular Diseases - prevention & control ; Drug Substitution - methods ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - pathology ; Female ; Heterocyclic Compounds, 3-Ring - administration & dosage ; Heterocyclic Compounds, 3-Ring - adverse effects ; HIV Infections - drug therapy ; HIV Integrase Inhibitors - administration & dosage ; HIV Integrase Inhibitors - adverse effects ; HIV Protease Inhibitors - administration & dosage ; HIV Protease Inhibitors - adverse effects ; Humans ; Life Sciences ; Lipids - blood ; Male ; Middle Aged ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical infectious diseases, 2019-02, Vol.68 (4), p.597-606</ispartof><rights>The Author(s) 2018</rights><rights>The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-cb03b02b1aadffb51c8ef055d6cd3bfdf977a94610c761eb6584af930f77af3c3</citedby><cites>FETCH-LOGICAL-c409t-cb03b02b1aadffb51c8ef055d6cd3bfdf977a94610c761eb6584af930f77af3c3</cites><orcidid>0000-0002-5724-3914 ; 0000-0002-5093-4800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29912307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-03727804$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Gatell, José M.</creatorcontrib><creatorcontrib>Assoumou, Lambert</creatorcontrib><creatorcontrib>Moyle, Graeme</creatorcontrib><creatorcontrib>Waters, Laura</creatorcontrib><creatorcontrib>Johnson, Margaret</creatorcontrib><creatorcontrib>Domingo, Pere</creatorcontrib><creatorcontrib>Fox, Julie</creatorcontrib><creatorcontrib>Martinez, Esteban</creatorcontrib><creatorcontrib>Stellbrink, Hans-Jürgen</creatorcontrib><creatorcontrib>Guaraldi, Giovanni</creatorcontrib><creatorcontrib>Masia, Mar</creatorcontrib><creatorcontrib>Gompels, Mark</creatorcontrib><creatorcontrib>De Wit, Stephane</creatorcontrib><creatorcontrib>Florence, Eric</creatorcontrib><creatorcontrib>Esser, Stefan</creatorcontrib><creatorcontrib>Raffi, François</creatorcontrib><creatorcontrib>Stephan, Christoph</creatorcontrib><creatorcontrib>Rockstroh, Juergen</creatorcontrib><creatorcontrib>Giacomelli, Andrea</creatorcontrib><creatorcontrib>Vera, Jaime</creatorcontrib><creatorcontrib>Bernardino, José Ignacio</creatorcontrib><creatorcontrib>Winston, Alan</creatorcontrib><creatorcontrib>Saumoy, Maria</creatorcontrib><creatorcontrib>Gras, Julien</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>Pozniak, Anton L.</creatorcontrib><creatorcontrib>European Network for AIDS Treatment 022 (NEAT022) Study Group</creatorcontrib><title>Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Both immediate and deferred switching from a PI/r-based to a DTG-based regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved lipid profiles.
Abstract
Background
Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile.
Methods
European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with a Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients were randomized to switch from PI/r to DTG immediately (DTG-I) or to deferred switch at week 48 (DTG-D). Week 96 endpoints were proportion of patients with HIV RNA <50 copies/mL, percentage change of lipid fractions, and adverse events (AEs).
Results
Four hundred fifteen patients were randomized: 205 to DTG-I and 210 DTG-D. The primary objective of noninferiority at week 48 was met. At week 96, treatment success rate was 92.2% in the DTG-I arm and 87% in the DTG-D arm (difference, 5.2% [95% confidence interval, -.6% to 11%]). There were 5 virological failures in the DTG-I arm and 5 (1 while on PI/r and 4 after switching to DTG) in the DTG-D arm without selection of resistance mutations. There was no significant difference in terms of grade 3 or 4 AEs or treatment-modifying AEs. Total cholesterol and other lipid fractions (except high-density lipoprotein) significantly (P < .001) improved both after immediate and deferred switching to DTG overall and regardless of baseline PI/r strata.
Conclusions
Both immediate and deferred switching from a PI/r to a DTG regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved the lipid profile.
Clinical Trials Registration
NCT02098837 and EudraCT: 2013-003704-39.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>ARTICLES AND COMMENTARIES</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Drug Substitution - methods</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - pathology</subject><subject>Female</subject><subject>Heterocyclic Compounds, 3-Ring - administration & dosage</subject><subject>Heterocyclic Compounds, 3-Ring - adverse effects</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Integrase Inhibitors - administration & dosage</subject><subject>HIV Integrase Inhibitors - adverse effects</subject><subject>HIV Protease Inhibitors - administration & dosage</subject><subject>HIV Protease Inhibitors - adverse effects</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQhyMEoqVw4Q7ypRIgBcbxOn-Oy5ayK61E1UIRp8hxxlmXJA62s2hvXDnzDDwNb9EnwauUIi4cRjP6zaff5YuixxReUijYK6nrMDsO_E50SDnL4pQX9G64gefxLGf5QfTAuSsASnPg96ODpChowiA7jH6tug5rLTySS7RudOQEFVqLNbn4qr3c6L4hp9Z0RJDXxjgfHmfWeBQOyarf6Ep7Y6-__ahCUJNzbHSHPfEm8CemHT02Vmy1jf_9655camta02gp2nZHLsZhsOj2zJnwGnvvyEftN2Spmw1ZCFtrsxVOjq2w5Fy7z8RYMm-QXH__yYF8QmHdw-ieEq3DRzf7KPpw-ub9Yhmv371dLebrWM6g8LGsgFWQVFSIWqmKU5mjAs7rVNasUrUqskwUs5SCzFKKVcrzmVAFAxVyxSQ7ip5PvRvRloPVnbC70ghdLufrcp8By5Ish9mWBvbZxA7WfBnR-bLTTmLbih7N6MoEeJqlScGygL6YUGmNcxbVbTeFci-6DKLLSXSAn970jlUQeIv-MRuA4wkw4_D_oicTd-WCyL89aZpQlgP7DSEvwGI</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Gatell, José M.</creator><creator>Assoumou, Lambert</creator><creator>Moyle, Graeme</creator><creator>Waters, Laura</creator><creator>Johnson, Margaret</creator><creator>Domingo, Pere</creator><creator>Fox, Julie</creator><creator>Martinez, Esteban</creator><creator>Stellbrink, Hans-Jürgen</creator><creator>Guaraldi, Giovanni</creator><creator>Masia, Mar</creator><creator>Gompels, Mark</creator><creator>De Wit, Stephane</creator><creator>Florence, Eric</creator><creator>Esser, Stefan</creator><creator>Raffi, François</creator><creator>Stephan, Christoph</creator><creator>Rockstroh, Juergen</creator><creator>Giacomelli, Andrea</creator><creator>Vera, Jaime</creator><creator>Bernardino, José Ignacio</creator><creator>Winston, Alan</creator><creator>Saumoy, Maria</creator><creator>Gras, Julien</creator><creator>Katlama, Christine</creator><creator>Pozniak, Anton L.</creator><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-5724-3914</orcidid><orcidid>https://orcid.org/0000-0002-5093-4800</orcidid></search><sort><creationdate>20190201</creationdate><title>Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years</title><author>Gatell, José M. ; Assoumou, Lambert ; Moyle, Graeme ; Waters, Laura ; Johnson, Margaret ; Domingo, Pere ; Fox, Julie ; Martinez, Esteban ; Stellbrink, Hans-Jürgen ; Guaraldi, Giovanni ; Masia, Mar ; Gompels, Mark ; De Wit, Stephane ; Florence, Eric ; Esser, Stefan ; Raffi, François ; Stephan, Christoph ; Rockstroh, Juergen ; Giacomelli, Andrea ; Vera, Jaime ; Bernardino, José Ignacio ; Winston, Alan ; Saumoy, Maria ; Gras, Julien ; Katlama, Christine ; Pozniak, Anton L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-cb03b02b1aadffb51c8ef055d6cd3bfdf977a94610c761eb6584af930f77af3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>ARTICLES AND COMMENTARIES</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Drug Substitution - methods</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - pathology</topic><topic>Female</topic><topic>Heterocyclic Compounds, 3-Ring - administration & dosage</topic><topic>Heterocyclic Compounds, 3-Ring - adverse effects</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Integrase Inhibitors - administration & dosage</topic><topic>HIV Integrase Inhibitors - adverse effects</topic><topic>HIV Protease Inhibitors - administration & dosage</topic><topic>HIV Protease Inhibitors - adverse effects</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gatell, José M.</creatorcontrib><creatorcontrib>Assoumou, Lambert</creatorcontrib><creatorcontrib>Moyle, Graeme</creatorcontrib><creatorcontrib>Waters, Laura</creatorcontrib><creatorcontrib>Johnson, Margaret</creatorcontrib><creatorcontrib>Domingo, Pere</creatorcontrib><creatorcontrib>Fox, Julie</creatorcontrib><creatorcontrib>Martinez, Esteban</creatorcontrib><creatorcontrib>Stellbrink, Hans-Jürgen</creatorcontrib><creatorcontrib>Guaraldi, Giovanni</creatorcontrib><creatorcontrib>Masia, Mar</creatorcontrib><creatorcontrib>Gompels, Mark</creatorcontrib><creatorcontrib>De Wit, Stephane</creatorcontrib><creatorcontrib>Florence, Eric</creatorcontrib><creatorcontrib>Esser, Stefan</creatorcontrib><creatorcontrib>Raffi, François</creatorcontrib><creatorcontrib>Stephan, Christoph</creatorcontrib><creatorcontrib>Rockstroh, Juergen</creatorcontrib><creatorcontrib>Giacomelli, Andrea</creatorcontrib><creatorcontrib>Vera, Jaime</creatorcontrib><creatorcontrib>Bernardino, José Ignacio</creatorcontrib><creatorcontrib>Winston, Alan</creatorcontrib><creatorcontrib>Saumoy, Maria</creatorcontrib><creatorcontrib>Gras, Julien</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>Pozniak, Anton L.</creatorcontrib><creatorcontrib>European Network for AIDS Treatment 022 (NEAT022) Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gatell, José M.</au><au>Assoumou, Lambert</au><au>Moyle, Graeme</au><au>Waters, Laura</au><au>Johnson, Margaret</au><au>Domingo, Pere</au><au>Fox, Julie</au><au>Martinez, Esteban</au><au>Stellbrink, Hans-Jürgen</au><au>Guaraldi, Giovanni</au><au>Masia, Mar</au><au>Gompels, Mark</au><au>De Wit, Stephane</au><au>Florence, Eric</au><au>Esser, Stefan</au><au>Raffi, François</au><au>Stephan, Christoph</au><au>Rockstroh, Juergen</au><au>Giacomelli, Andrea</au><au>Vera, Jaime</au><au>Bernardino, José Ignacio</au><au>Winston, Alan</au><au>Saumoy, Maria</au><au>Gras, Julien</au><au>Katlama, Christine</au><au>Pozniak, Anton L.</au><aucorp>European Network for AIDS Treatment 022 (NEAT022) Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>68</volume><issue>4</issue><spage>597</spage><epage>606</epage><pages>597-606</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Both immediate and deferred switching from a PI/r-based to a DTG-based regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved lipid profiles.
Abstract
Background
Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile.
Methods
European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with a Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients were randomized to switch from PI/r to DTG immediately (DTG-I) or to deferred switch at week 48 (DTG-D). Week 96 endpoints were proportion of patients with HIV RNA <50 copies/mL, percentage change of lipid fractions, and adverse events (AEs).
Results
Four hundred fifteen patients were randomized: 205 to DTG-I and 210 DTG-D. The primary objective of noninferiority at week 48 was met. At week 96, treatment success rate was 92.2% in the DTG-I arm and 87% in the DTG-D arm (difference, 5.2% [95% confidence interval, -.6% to 11%]). There were 5 virological failures in the DTG-I arm and 5 (1 while on PI/r and 4 after switching to DTG) in the DTG-D arm without selection of resistance mutations. There was no significant difference in terms of grade 3 or 4 AEs or treatment-modifying AEs. Total cholesterol and other lipid fractions (except high-density lipoprotein) significantly (P < .001) improved both after immediate and deferred switching to DTG overall and regardless of baseline PI/r strata.
Conclusions
Both immediate and deferred switching from a PI/r to a DTG regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved the lipid profile.
Clinical Trials Registration
NCT02098837 and EudraCT: 2013-003704-39.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>29912307</pmid><doi>10.1093/cid/ciy505</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5724-3914</orcidid><orcidid>https://orcid.org/0000-0002-5093-4800</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2019-02, Vol.68 (4), p.597-606 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03727804v1 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Antiretroviral Therapy, Highly Active - methods ARTICLES AND COMMENTARIES Cardiovascular Diseases - prevention & control Drug Substitution - methods Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - adverse effects HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - adverse effects Humans Life Sciences Lipids - blood Male Middle Aged Treatment Outcome Young Adult |
| title | Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T17%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immediate%20Versus%20Deferred%20Switching%20From%20a%20Boosted%20Protease%20Inhibitor%E2%80%93based%20Regimen%20to%20a%20Dolutegravir-based%20Regimen%20in%20Virologically%20Suppressed%20Patients%20With%20High%20Cardiovascular%20Risk%20or%20Age%20%E2%89%A550%20Years:%20Final%2096-Week%20Results%20of%20the%20NEAT022%20Study&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Gatell,%20Jos%C3%A9%20M.&rft.aucorp=European%20Network%20for%20AIDS%20Treatment%20022%20(NEAT022)%20Study%20Group&rft.date=2019-02-01&rft.volume=68&rft.issue=4&rft.spage=597&rft.epage=606&rft.pages=597-606&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciy505&rft_dat=%3Cjstor_hal_p%3E26621380%3C/jstor_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2056762937&rft_id=info:pmid/29912307&rft_jstor_id=26621380&rft_oup_id=10.1093/cid/ciy505&rfr_iscdi=true |